Pharmacological targeting of the constitutively activated MEK/MAPK-dependent signaling pathway in glioma cells inhibits cell proliferation and migration

International Journal of Oncology

Volumn 39, Issue 6, 2011, Pages 1567-1575

  Glassmann, Alexander ^a,c   Reichmann, Karl ^a   Scheffler, Björn ^b   Glas, Martin ^b   Veit, Nadine ^a   Probstmeier, Rainer ^a  

^a UNIVERSITY OF BONN   (Germany)

^b UNIVERSITY HOSPITAL BONN   (Germany)

^c Life Science Inkubator   (Germany)

Author keywords

Extracellular signal regulated kinases 1 2; Glioma; Invasion; MEK; Migration; Mitogen activated protein kinase; Proliferation; U0126

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3;

ANIMAL CELL; ARTICLE; CANCER INHIBITION; CARCINOGENESIS; CELL CYCLE ARREST; CELL CYCLE PROGRESSION; CELL LINE; CELL MIGRATION; CELL PROLIFERATION; ENZYME ACTIVATION; ENZYME ACTIVITY; GLIOMA CELL; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; RAT; SIGNAL TRANSDUCTION; TUMOR GROWTH;

ANIMALS; BUTADIENES; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; ENZYME INHIBITORS; GLIOMA; HUMANS; MAP KINASE SIGNALING SYSTEM; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; NEOPLASTIC STEM CELLS; NITRILES; RATS;

EID: 80054829310     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2011.1165     Document Type: Article

References (29)

1. Pearson G, Robinson F, Beers GT, Xu BE, Karandikar M, Berman K and Cobb MH: Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions. Endocr Rev 22: 153-183, 2001. (Pubitemid 32458157)
2. Sebolt-Leopold JS and Herrera R: Targeting the mitogen-activated protein kinase cascade to treat cancer. Nat Rev Cancer 4: 937-947, 2004. (Pubitemid 39626217)
3. Ebisuya M, Kondoh K and Nishida E: The duration, magnitude and compartmentalization of ERK MAP kinase activity: mechanisms for providing signaling specificity. J Cell Sci 118: 2997-3002, 2005. (Pubitemid 41149904)
4. Hoshino R, Chatani Y, Yamori T, et al.: Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors. Oncogene 18: 813-822, 1999. (Pubitemid 29080340)
5. Towatari M, Iida H, Tanimoto M, Iwata H, Hamaguchi M and Saito H: Constitutive activation of mitogen-activated protein kinase pathway in acute leukemia cells. Leukemia 11: 479-484, 1997. (Pubitemid 27173933)
6. Bhaskara VK, Panigrahi M, Challa S and Babu PP: Comparative status of activated ERK1/2 and PARP cleavage in human gliomas. Neuropathology 25: 48-53, 2005. (Pubitemid 40477712)
7. Mandell JW, Hussaini IM, Zecevic M, Weber MJ and Vandenberg SR: In situ visualization of intratumor growth factor signaling: immunohistochemical localization of activated ERK/ MAP kinase in glial neoplasms. Am J Pathol 153: 1411-1423, 1998. (Pubitemid 28509897)
8. Mawrin C, Diete S, Treuheit T, et al.: Prognostic relevance of MAPK expression in glioblastoma multiforme. Int J Oncol 23: 641-648, 2003.
9. Pelloski CE, Lin E, Zhang L, et al.: Prognostic associations of activated mitogen-activated protein kinase and Akt pathways in glioblastoma. Clin Cancer Res 12: 3935-3941, 2006. (Pubitemid 44078078)
10. Merlo A: Genes and pathways driving glioblastomas in humans and murine disease models. Neurosurg Rev 26: 145-158, 2003.
11. Kapoor GS and O'Rourke DM: Receptor tyrosine kinase signaling in gliomagenesis: pathobiology and therapeutic approaches. Cancer Biol Ther 2: 330-342, 2003.
12. Davies SP, Reddy H, Caivano M and Cohen P: Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J 351: 95-105, 2000.
13. Vladimirova V, Waha A, Luckerath K, Pesheva P and Probstmeier R: Runx2 is expressed in human glioma cells and mediates the expression of galectin-3. J Neurosci Res 86: 2450-2461, 2008.
14. Glas M, Rath BH, Simon M, et al.: Residual tumor cells are unique cellular targets in glioblastoma. Ann Neurol 68: 264-269, 2010.
15. Wee S, Jagani Z, Xiang KX, et al.: PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers. Cancer Res 69: 4286-4293, 2009.
16. Mirza AM, Gysin S, Malek N, Nakayama K, Roberts JM and McMahon M: Cooperative regulation of the cell division cycle by the protein kinases RAF and AKT. Mol Cell Biol 24: 10868-10881, 2004. (Pubitemid 39603142)
17. MacKeigan JP, Murphy LO, Dimitri CA and Blenis J: Graded mitogen-activated protein kinase activity precedes switch-like c-Fos induction in mammalian cells. Mol Cell Biol 25: 4676-4682, 2005. (Pubitemid 40705770)
18. Frieboes HB, Lowengrub JS, Wise S, Zheng X, Macklin P, Bearer EL and Cristini V: Computer simulation of glioma growth and morphology. Neuroimage 37 (Suppl 1): S59-S70, 2007. (Pubitemid 47239426)
19. Krueger JS, Keshamouni VG, Atanaskova N and Reddy KB: Temporal and quantitative regulation of mitogen-activated protein kinase (MAPK) modulates cell motility and invasion. Oncogene 20: 4209-4218, 2001. (Pubitemid 32762195)
20. Klemke RL, Cai S, Giannini AL, Gallagher PJ, de Lanerolle P and Cheresh DA: Regulation of cell motility by mitogen-activated protein kinase. J Cell Biol 137: 481-492, 1997. (Pubitemid 27181299)
21. Webb DJ, Nguyen DH and Gonias SL: Extracellular signal-regulated kinase functions in the urokinase receptor-dependent pathway by which neutralization of low density lipoprotein receptor-related protein promotes fibrosarcoma cell migration and matrigel invasion. J Cell Sci 113: 123-134, 2000. (Pubitemid 30066339)
22. Joy AM, Beaudry CE, Tran NL, Ponce FA, Holz DR, Demuth T and Berens ME: Migrating glioma cells activate the PI3-K pathway and display decreased susceptibility to apoptosis. J Cell Sci 116: 4409-4417, 2003. (Pubitemid 37369596)
23. Sahai E: Mechanisms of cancer cell invasion. Curr Opin Genet Dev 15: 87-96, 2005.
24. Robinson JP, Vanbrocklin MW, Lastwika KJ, McKinney AJ, Brandner S and Holmen SL: Activated MEK cooperates with Ink4a/Arf loss or Akt activation to induce gliomas in vivo. Oncogene 30: 1341-1350, 2011.
25. Molina JR, Hayashi Y, Stephens C and Georgescu MM: Invasive glioblastoma cells acquire stemness and increased Akt activation. Neoplasia 12: 453-463, 2010.
26. De Witt Hamer PC: Small molecule kinase inhibitors in glioblastoma: a systematic review of clinical studies. Neuro Oncol 12: 304-316, 2010.
27. Mercer RW, Tyler MA, Ulasov IV and Lesniak MS: Targeted therapies for malignant glioma: progress and potential. BioDrugs 23: 25-35, 2009.
28. Thaker NG and Pollack IF: Molecularly targeted therapies for malignant glioma: rationale for combinatorial strategies. Expert Rev Neurother 9: 1815-1836, 2009.
29. Hecker D, Kappler J, Glassmann A, Schilling K and Alt W: Image analysis of time-lapse movies - a precision control guided approach to correct motion artefacts. J Neurosci Meth 172: 67-73, 2008.